Yahoo Finance

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...
Medindia

Fibroscan for Fatty Liver Cirrhosis and Fibrosis

The Fibroscan test is recognized in the medical community as an established procedure to assess liver fibrosis. It received FDA approval in 2012. A simple probe is placed on the skin in between the ...
Healthline

Could a FibroScan Detect Liver Cancer?

According to the Centers for Disease Control and Prevention (CDC), approximately 25,000 men and 11,000 women are diagnosed with liver cancer each year. Early detection and treatment are key to ...
manilatimes

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development This is the first time the FDA is ...